News

The company is restructuring its R&D organization to accelerate the expansion and diversification of its pipeline across severe chronic diseases, in addition to supporting increased investment in transformational

The CLR 131 is an investigational radioiodinated PDC therapy, which exploits the tumor-targeting properties of the firm’s phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to

Respivant will be led by chief executive officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and

Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access

Presented as a late-breaking oral presentation at the European Respiratory Society (ERS) meeting in France, the PORtopulmonary hypertension Treatment wIth maCitentan ─ a randOmized clinical trial (PORTICO) showed

Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make

Alopecia areata is an autoimmune disease evidenced by hair loss and often linked with profound psychological consequences. The PF-06651600 is an oral JAK 3 inhibitor, while PF-06700841 is a

AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for

Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive